HDAC9 and chondrosarcoma: In addition, our study identifies glutaminolysis and Bcl-2 family member inhibitors as potential candidates to be used in combination with HDAC inhibition, suggesting that romidepsin influences the metabolic state and apoptotic threshold of chondrosarcoma cells.